Skip to main content


COVID-19 Business Continuity

Business Continuity

Johnson & Johnson business continuity plans during the coronavirus (COVID-19) outbreak

Last Update: August 2020 

In our role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 (coronavirus) situation and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.

We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products.

These steps include maintaining critical inventory at major distribution centres away from high-risk areas and working with external suppliers to support our preparedness plans. We currently have sufficient inventory for critical patient needs and are working diligently to minimise patient, customer and consumer impact.

We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution.

While this remains a dynamic situation, we do not foresee pharmaceutical supply interruptions related to COVID-19 at this time. As a leader in global health, our top priority remains our patients, customers and employees. We are partnering with global and local health authorities to collaborate in addressing the immediate and long term needs to ensure a sustainable supply of our critical medicines as well as researching potential vaccines and therapeutics.

We will remain on the front line of this health crisis, bringing our full resources and minds to combat it.

For patients with questions regarding their medication, we advise speaking to your GP or healthcare professional.

For healthcare professionals with questions regarding Janssen products in light of the current coronavirus situation, please contact our Medical Information Team on 01494 567 444 or by e-mail at: [email protected].

If your enquiry is related to an adverse event associated with a Janssen product, please contact our Drug Safety Department on 01494 567447 or by e-mail at: [email protected].

The Janssen UK Team